This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Oblimersen
- DrugBank Accession Number
- DB13811
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Synonyms
- Oblimersen
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Oblimersen is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- ATC Codes
- L01XX36 — Oblimersen
- Drug Categories
- Antineoplastic Agents
- Antineoplastic and Immunomodulating Agents
- Antisense Elements (Genetics)
- Antisense Oligonucleotides
- Compounds used in a research, industrial, or household setting
- DNA, Antisense
- Laboratory Chemicals
- Molecular Probes
- Nucleic Acid Probes
- Nucleic Acids
- Nucleic Acids, Nucleotides, and Nucleosides
- Nucleotides
- Oligodeoxyribonucleotides, Antisense
- Oligonucleotides
- Polynucleotides
- Sulfur Compounds
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 85J5ZP6YSL
- CAS number
- 190977-41-4
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Not Available
- External Links
- Wikipedia
- Oblimersen
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Completed Treatment Melanoma 1 2 Terminated Treatment Melanoma 1 2, 3 Terminated Treatment Advanced Melanoma and Normal or Impaired / Hepatic Function 1 1 Completed Health Services Research Mildly Impaired Renal Function / Moderately Impaired Renal Function / Normal Renal Function 1 1 Completed Treatment Solid Tumors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at June 23, 2017 20:49 / Updated at February 21, 2021 18:54